AngioDynamics (ANGO) Scheduled to Post Quarterly Earnings on Thursday

AngioDynamics (NASDAQ:ANGO) is scheduled to be announcing its earnings results before the market opens on Thursday, October 3rd. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. AngioDynamics has set its FY25 guidance at ($0.42)-($0.38) EPS and its FY 2025 guidance at -0.420–0.380 EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.11. The firm had revenue of $71.00 million for the quarter, compared to analyst estimates of $70.86 million. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The business’s revenue was down 22.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.02 earnings per share. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Performance

ANGO stock opened at $7.40 on Thursday. The stock has a fifty day moving average of $7.49 and a 200-day moving average of $6.54. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $8.25. The company has a market capitalization of $296.41 million, a price-to-earnings ratio of -1.53 and a beta of 0.65.

Wall Street Analysts Forecast Growth

ANGO has been the subject of several analyst reports. Canaccord Genuity Group cut their target price on AngioDynamics from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.25.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.